Method of determining a site of inflammation utilizing elam-1 ligands

US5143712A · kind A · utility

Assignee

• Glycomed Incorporated · US

Inventors

• Brian K. Brandley · Alameda, US
• Michael Tiemeyer · Oakland, US
• Stuart J. Swiedler · Oakland, US
• Margaret Moreland · Berkeley, US
• Hans Schweingruber · Mountain View, US

Key dates

• Filing date: Jan 7, 1991
• Grant date: Sep 1, 1992
• Expiry date: Jan 7, 2011

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2123/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of A and B is hydrogen and one is an N-acetyl neuraminic acid residue; D and E are each independently hydrogen or a fucose residue; n is an integer of from 0 to 10 with the proviso that if n is 0, E is a fucose residue; F is hydrogen, a lactosylceramide residue or a linking group; and molecules equivalent to a compound of formula I regarding its ability to bind to an ELAM-1 receptor to the same degree as a compound of formula I.